RU2538218C2 - Drug for treating osteoarthrosis (versions) - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: invention represents a drug for treating osteoarthrosis presented as a soft dosage form, containing glucosamine and methyl salicylate as active substances, and additive agents.

EFFECT: enhanced anaesthetic action and lower toxicity of methyl salicylate.

10 cl, 1 tbl, 4 ex

Description

The invention relates to the pharmaceutical industry, namely to the production of medicines for the treatment of osteoarthritis. The invention is a medicament consisting of a combination of two or three active substances, one of which is a glucosamine salt, mainly glucosamine hydrochloride, and auxiliary substances. The drug is in the form of a cream-gel, cream, but is not limited to this.

Osteoarthrosis is a degenerative joint disease caused by damage to the cartilage of the articular surfaces [1].

The main clinical symptoms of osteoarthritis are pain and joint deformation, leading to functional failure [2].

Osteoarthritis is the most common form of joint damage and one of the main causes of disability, causing a deterioration in the quality of life and significant financial costs, especially in older people.

Osteoarthrosis is common. In the United States, 21 million people are ill (approximately 7% of the population). A large-scale study in 7 cities of the former USSR revealed manifest (accompanied by clinical symptoms) osteoarthritis in 6.43% of the examined (41348 people over 15 years old) [3].

The incidence of osteoarthritis increases sharply with age, reaching one third of the population in the elderly and senile.

According to the modern classification of drugs used in the treatment of osteoarthritis, they are divided into the following groups:

1. Symptomatic fast-acting drugs (non-steroidal anti-inflammatory drugs, acetaminophen, opioid analgesics, corticosteroids, etc.) that affect the clinical symptoms of the disease (pain, inflammation, etc.).

2. Modifying agents of delayed action (glucosamine, chondroitin, hyaluronic acid), the effect of which is manifested more slowly compared to symptomatic agents and lasts after the end of their use. These pharmacological agents have a chondromodifying effect, preventing the degradation of articular cartilage [4].

Glucosamine has chondroprotective properties, reduces the deficiency of glycosaminoglycans in the body, is a specific substrate and stimulator of the synthesis of hyaluronic acid and proteoglycans. It improves joint mobility, reduces the need for non-steroidal anti-inflammatory drugs (NSAIDs) [5].

The closest analogue to the present invention is the drug "Pharmaskin THC" with the active substance glucosamine sulfate potassium chloride 4 g in the form of a cream for external use.

The disadvantage of the drug is a weak analgesic and anti-inflammatory effect.

The aim of the present invention is to develop an effective drug for the treatment of osteoarthritis, which has an enhanced effect on the source of inflammation and pain by effective permeability of the active substances through the skin and combines both chondroprotective, anti-inflammatory and analgesic effects.

The technical result of the invention is:

1. Strengthening the analgesic and anti-inflammatory properties of drugs with chondroprotective effects.

The technical result is achieved by introducing into the composition of the drug methyl salicylate with a dosage of 0.1-5.0% by weight, preferably 2.50% by weight, and / or lidocaine salt with a dosage of 0.1-5.0% by weight, mainly lidocaine hydrochloride with a dosage of 1.0% of the mass.

Methyl salicylate is an anti-inflammatory painkiller. Non-selectively inhibits cyclooxygenase, reducing prostaglandin synthesis. It normalizes the increased permeability of capillaries, improves microcirculation processes, reduces edema and infiltration of inflamed tissues. When applied topically, methyl salicylate penetrates the tissues through unchanged skin, while an analgesic concentration in the systemic circulation is not achieved.

Lidocaine - a local anesthetic; anesthesia is achieved by suppressing the formation and conduction of nerve impulses along afferent nerve fibers by depolarization of sodium channels.

2. The expansion of the arsenal of tools for the production of medicines containing glucosamine salt as the active substance.

The technical result is achieved through the use of excipients as a pharmaceutically acceptable preservative (preservatives) with a dosage of 0.0001-2.0 wt%, mainly phenoxyethanol with a dosage of 0.50 wt%, methyl paraben with a dosage of 0.15-0.20 % wt., pronyl paraben with a dosage of 0.05% wt., benzalkonium chloride with a dosage of 0.01% wt., benzyl alcohol with a dosage of 0.5% wt., but not limited to.

The drug contains an antioxidant with a dosage of 0.05-2.0 wt.%, Mainly: butylhydroxyanisole with a dosage of 0.20 wt.%, Butylhydroxytoluene with a dosage of 0.10 wt.%, Sodium metabisulfite with a dosage of 0.10 wt. but not limited to this.

The composition of the drug includes solvents with a dosage of 5.0-60.0% by weight, mainly as solvents: N-methylpyrrolidone with a dosage of 15.00% by weight, propylene glycol with a dosage of 10.00% by weight, polyethylene oxide 400 with a dosage 10.00-20.00% by weight, hexylene glycol with a dosage of 8.00-15.00% by weight, 2-pyrrolidone with a dosage of 20.00% by weight, diethylene glycol monomethyl ether with a dosage of 7.00% by weight, butylene glycol with a dosage of 12.00% of the mass., but not limited to this.

The drug includes emulsifiers with a dosage of 0.5-15.0% by mass., As emulsifiers it mainly contains: macrogol 20 cetostearyl ether with a dosage of 1.40-2.00% by mass. and cetostearyl alcohol with a dosage of 3.50-6.80% by mass., glyceryl monostearate with a dosage of 2.30% by mass., cetyl alcohol with a dosage of 3.00-5.00% by mass., stearyl alcohol with a dosage of 0.80-2 , 50% by weight, macrogol hydroxystearate with a dosage of 1.60% by weight, sorbitan monolaurate with a dosage of 1.50% by weight, polysorbate 20 with a dosage of 5.00% by weight, but not limited to.

The composition of the drug includes a thickener (thickeners) with a dosage of 0.1-7.0% by weight, mainly hydroxypropyl starch phosphate with a dosage of 2.50-6.00% by weight, hydroxypropyl methylcellulose with a dosage of 1.5% by weight, hydroxyethyl starch with with a dosage of 5.00 wt.%, hydroxypropyl cellulose with a dosage of 5.00 wt.%, methyl cellulose with a dosage of 0.10 wt.%, but not limited to.

The composition of the drug includes emollients with a dosage of 3.0-80.0% by weight, mainly: isopropyl myristate with a dosage of 3.50-5.00% by weight, dimethicone DM 100 with a dosage of 1.00-3.00% by weight. , hexyl decyl stearate with a dosage of 6.30% by weight, white wax with a dosage of 3.40% by weight, white soft paraffin (white petrolatum) with a dosage of 25.00-65.00% by weight, isopropyl palmitate with a dosage of 5.00% by weight ., cyclomethicone with a dosage of 1.00% wt., vaseline oil with a dosage of 7.00% wt., emulsion wax with a dosage of 3.00% wt., anhydrous lanolin with a dosage of 15.00% wt., octyldodecanol with a dosage of 1 , 50-5.50% of the mass., But not limited to this.

Isopropyl myristate and dimethicone DM 100 have a softening effect on the skin.

The medicinal product contains a pH regulating agent with a dosage of 0.1-2.0% by weight, mainly citric acid monohydrate with a dosage of 0.20-0.80% by weight, sodium citrate with a dosage of 0.35% by weight, phosphoric acid with a dosage of 0.20% of the mass., sodium hydroxide with a dosage of 0.1% of the mass., but not limited to.

As a solvent and the main component of the base, the drug contains purified water to 100% of the mass.

The invention is a medicament consisting of a combination of two or three active substances, one of which is a glucosamine salt, mainly glucosamine hydrochloride, and auxiliary substances. The drug is in the form of a cream-gel, cream, but is not limited to this.

A drug has been developed with the active substances glucosamine salt, mainly glucosamine hydrochloride, and methyl salicylate. The preferred composition of the medicinal product,% mass .:

- glucosamine hydrochloride - 0.5-10.0

- methyl salicylate - 0.1-5.0

- preservative (preservatives) - 0.0001-2.0

- antioxidant (antioxidants) - 0.05-2.0

non-aqueous solvent (s) - 5.0-60.0

- emulsifier (emulsifiers) - 0.5-15.0

- thickener - 0.1-7.0

- emollients - 3.0-80.0

- pH adjusting agent (s) - 0.1-2.0

- purified water - the rest is up to 100%.

The drug can be made in the form of a cream-gel, cream, but is not limited to this.

Example 1. The drug in the form of a cream of the following composition,% mass .:

- glucosamine hydrochloride - 5.0

- methyl salicylate - 2.5

- phenoxyethanol - 0.50

- butylhydroxyanisole - 0.20

- N-methylpyrrolidone - 15.00

- propylene glycol - 10.00

- macrogol 20 cetostearyl ether - 2.00

- cetosterial alcohol - 6.80

- hydroxypropyl starch phosphate - 2.50

- isopropyl myristate - 5.0

- Dimethicone DM 100 - 3.0

- octyldodecanol - 5.50

- hexyl decyl stearate - 6.30

- citric acid monohydrate - 0.50

- purified water - the rest is up to 100%.

The method for producing the medicine of Example 1 includes preparing an aqueous solution of glucosamine hydrochloride, preparing a non-aqueous solution of an antioxidant and methyl salicylate, preparing a base, introducing a preservative into the base, shifting the base with the first two solutions, mixing until the finished drug is obtained, packing in tubes or jars.

Under the basis in the present invention should be understood a mixture of non-aqueous solvent (s), a thickener, a pH adjusting agent, emulsifiers and emollients.

3 preclinical studies of a drug with active substances — glucosamine hydrochloride and methyl salicylate (working name “Glucosamine plus”) in the form of a cream gel were carried out, samples of which were produced at OAO Tatkhimpharmpreparat:

1. A preclinical study of the chondroprotective properties of the drug “Glucosamine Plus” (cream gel), conducted at the National Pharmaceutical University of the Ministry of Health of Ukraine, Kharkov, 2011

2. Preclinical toxicological study (acute and subchronic toxicity, local irritating effect) of the drug “Glucosamine plus” (cream-gel), conducted in the State Enterprise “GNTsLS”, Kharkov, 05.08.2011.

3. A preclinical study of the specific pharmacological activity of the drug “Glucosamine plus” (cream gel), conducted in the State Enterprise “GNTsLS”, Kharkov, 08/05/2011

In the course of the studies, it was proved that the studied drug "Glucosamine Plus" (cream gel) exhibits pronounced chondroprotective activity.

This phenomenon is explained by the composition of the investigated funds. The drug “Glucosamine Plus” is an original pharmaceutical composition for external use, which contains a chondroprotector glucosamine hydrochloride and NSAIDs metisalicylate, which has anti-inflammatory, analgesic, distracting effects and helps potentiate the positive effect of chondroprotector on the course of inflammatory and destructive processes in the joints of the patient [6] ].

Thus, the analysis of the results indicates that the drug "Glucosamine Plus" (cream gel) is a promising tool for the treatment and prevention of degenerative joint diseases, especially against the background of exacerbation of the joint syndrome. The drug can be used both as monotherapy and as part of the complex treatment of osteoarthritis of damaged joints in high concentrations [6, p. 73].

The acute toxicity of the study drug was studied in rats with cutaneous applications at a dose of 3.0 g / kg. The results of the study of acute toxicity showed that the application of cream to rats does not cause death of animals, do not have a toxic effect on the general condition, behavior, body weight of animals, food and water consumption, do not affect the absolute and relative mass of the internal organs of rats, do not cause visible changes in them internal organs.

Subchronic toxicity was studied in experiments on rats with daily cutaneous applications at doses of 0.3 g / kg and 0.6 g / kg for a month. The results of the study showed that the use of the drug Glucosamine Plus cream-gel does not affect the general condition and behavior, food and water consumption, dynamics of animal body weight, the functional state of the central nervous system and electrophysiological activity of the myocardium, and biochemical parameters characterizing the functional state of the liver and kidneys of animals , on indicators characterizing peripheral blood.

By pathomorphological studies in a subchronic experiment, it was found that the drug Glucosamine Plus cream-gel in the studied doses does not affect the relative mass of the internal organs of rats. After prolonged exposure to the drug, there are no macroscopic and morphological signs of cardiotoxic and hepatotoxic effects on the body of experimental animals. The drug does not cause visible shifts in the morphofunctional state of the central (thymus) and peripheral (spleen) immunogenesis units. Glucosamine Plus cream-gel does not cause rearrangement in various parts of the adrenal cortex and the associated changes in the nature of mineralocorticoid synthesis.

According to macro- and microscopic examination of the skin, it was found that the drug Glucosamine Plus cream-gel does not have a locally irritating effect [7, p. 28].

The purpose of the preclinical pharmacological study of the drug Glucosamine Plus cream-gel (OAO Tatkhimpharmpreparaty) was to study the specific pharmacological (analgesic, anti-inflammatory) activity of the drug.

The analgesic and anti-inflammatory activity of the drug was studied in rats on a model of acute and subacute inflammatory pathology - with carrageenan and traumatic inflammation of the foot - in accordance with the basic principles set forth in the “Guidelines for the study of new non-steroidal anti-inflammatory drugs”.

Studies have been carried out in comparison with the basis of the cream gel Glucosamine Plus.

It was found that a double cutaneous application of Glucosamine Plus cream gel in a total dose of 200 mg / foot to rats with carrageenan edema of the foot has an analgesic and anti-inflammatory effect, which manifests itself in a significant increase in the threshold of pain sensitivity and a decrease in the volume of the inflamed foot of rats compared with the untreated group and rat group receiving the cream gel base. The analgesic effect of the drug was 101.8%, the anti-inflammatory effect was 23.9%.

The basis of the cream gel with two applications in the same total dose (200 mg / foot) did not significantly affect the threshold of pain sensitivity and the increase in the volume of inflamed foot compared with the control.

When applied to rats with traumatic inflammation of the foot in an 8-day dose in the same daily dose (200 mg / foot), Glucosamine Plus cream-gel has an analgesic effect, significantly increasing the threshold of pain sensitivity of an injured foot from 3 days of treatment compared to untreated control and the group, which caused the foundation. The analgesic effect of cream gel on day 3 was 80%, on day 5 - 74.4%, on day 7 - 71.6%. The total analgesic effect of the cream gel was 412.4, which is 2.7 times more than the group receiving the cream gel base - 153.0. In the group of rats receiving the cream-gel base, no significant differences with untreated control were observed.

In the same rats with traumatic edema, the studied drug, with daily applications, has an anti-inflammatory effect, significantly reducing the increase in foot edema by 2 days of treatment. The anti-inflammatory effect of the drug was: on day 1 - 10.2%, day 2 - 25.2%, day 3 - 48.2%, day 4 - 49.5%, day 5 - 50.9%, day 6 - 62 , 8%, 7 days - 71.6%, 8 days - 85.4%. The total anti-inflammatory effect of the cream-gel Glucosamine Plus was 361.1, which is 4.8 times more than its base - 74.5. The application of the cream gel base did not significantly reduce the increase in edema.

In general, the results of a study of the specific pharmacological (analgesic, anti-inflammatory) activity of the drug Glucosamine Plus cream-gel (OAO Tatkhimpharmpreparaty) with a single and long-term (course) use in rats on a model of acute and subacute inflammatory pathology indicate that the developed drug has pronounced analgesic and anti-inflammatory effect, due to the activity of the active components, as evidenced by a significantly greater severity pharmacologically x effects of the drug compared with a base that does not contain active substances [8, p.27-28].

Example 2. The drug is made in the form of a cream, including as active substances glucosamine salt and methyl salicylate, containing the following components,% wt .:

- glucosamine hydrochloride - 5.00

- methyl salicylate - 2.50

- methyl paraben - 0.20

- butylhydroxytoluene - 0.10

- polyethylene oxide 400 - 20.00

- hexylene glycol - 8.00

- glyceryl monostearate - 2.30

- cetyl alcohol - 3.00

- stearyl alcohol - 2.50

- hydroxypropyl methyl cellulose - 1.5

- isopropyl palmitate - 6.00

- cyclomethicone - 1.00

- liquid paraffin - 7.00

- sodium citrate - 0.35

- citric acid monohydrate - 0.20

- purified water - the rest is up to 100%.

A drug has been developed with the active substances glucosamine salt, mainly glucosamine hydrochloride, methyl salinylate and lidocaine salt, mainly lidocaine hydrochloride. The preferred composition of the medicinal product,% mass .:

- glucosamine hydrochloride - 0.5-10.0

- methyl salicylate - 0.1-5.0

- lidocaine hydrochloride - 0.1-5.0

- preservative (preservatives) - 0.0001-2.0

- antioxidant (antioxidants) - 0.05-2.0

- solvent (s) - 5.0-60.0

- emulsifier (emulsifiers) - 0.5-15.0

- thickener - 0.1-7.0

- emollients - 3.0-80.0

- pH adjusting agent (s) - 0.1-2.0

- purified water - the rest is up to 100%.

The drug can be made in the form of a cream-gel, cream, but is not limited to this.

Example 3. The drug in the form of a cream gel of the following composition,% mass .:

- glucosamine hydrochloride - 5.00

- methyl salicylate - 2.50

- lidocaine hydrochloride - 1.00

- phenoxyethanol - 0.50

- butylhydroxyanisole - 0.20

- N-methylpyrrolidone - 15.00

- propylene glycol - 10.00

- macrogol 20 cetostearyl ether - 1.40

- cetostearyl alcohol - 6.60

- hydroxypropyl starch phosphate - 4.00

- isopropyl myristate - 4.00

- Dimethicone DM 100 - 1.00

- citric acid monohydrate - 0.40

- purified water - the rest is up to 100%

The method for producing the medicine of Example 3 includes preparing an aqueous solution of glucosamine hydrochloride and lidocaine hydrochloride, preparing a non-aqueous solution of an antioxidant and methyl salicylate, preparing a base, introducing a preservative into the base, mixing the base with the first two solutions, mixing until the finished drug is obtained, packing in tubes or cans.

Example 4. A drug in the form of a cream-gel containing glucosamine salt, methyl salicylate, lidocaine salt as the active substance, the following composition,% wt .:

- glucosamine hydrochloride - 5.00

- methyl salicylate - 2.50

- lidocaine hydrochloride - 1.00

- benzalkonium chloride - 0.01

- butylhydroxytoluene - 0.10

- 2-pyrrolidone - 20.00

- diethylene glycol monomethyl ether - 7.00

- macrogol hydroxystearate - 1.60

- cetyl alcohol - 5.00

- hydroxyethyl starch - 5.00

- isopropyl palmitate - 5.00

- cyclomethicone - 1.00

- phosphoric acid - 0.20

- purified water - the rest is up to 100%.

Experimental studies have been carried out using the visual analogue scale method (hereinafter - YOUR), proving that the pharmaceutical composition containing glucosamine salt, methyl salicylate as active substances, as well as the pharmaceutical composition containing glucosamine salt, methyl salicylate and lidocaine salt as active substances, are made in soft dosage form, have improved analgesic properties compared to a pharmaceutical composition containing only glucose as an active substance to also formed in soft dosage forms.

The visual analogue scale is a ruler 100 mm long, a value of 0 mm corresponds to the best condition of the patient (no pain), a maximum value of 100 mm corresponds to the worst condition (maximum intensity of pain).

We studied the change in pain intensity in volunteers - patients with knee osteoarthritis when walking on a flat surface, and the initial value of pain intensity (before treatment) in all volunteers was more than 40 mm according to YOUR.

Volunteers were divided into 5 groups:

- the first group treated with the drug Pharmaskin THC in the form of a cream with the active substance glucocosamine sulfate potassium chloride;

- the second group treated with a pharmaceutical composition in the form of a cream containing glucosamine hydrochloride and methyl salicylate as active substances (example 1);

- the third group treated with a pharmaceutical composition in the form of a cream containing glucosamine hydrochloride and methyl salicylate as active substances (example 2);

- the fourth group treated with a pharmaceutical composition in the form of a cream gel containing glucosamine hydrochloride, methyl salicylate and lidocaine hydrochloride as active substances (example 3);

- the fifth group treated with a pharmaceutical composition in the form of a cream gel containing glucosamine hydrochloride, methyl salicylate and lidocaine hydrochloride as active substances (example 4).

In each group, there were 20 people, the average age of the volunteers in each group was in the range of 60-70 years, the average value of pain intensity within each group was more than 40 mm according to YOUR, the body mass index of all volunteers within each group was within the norm (18.5-25 kg / m ² ), the number of men and women within each group was equal to each other and amounted to 10 people.

As a result of the study of pain intensity using the VAS method, the following results were obtained (table 1).

Table 1 results of a study of pain intensity using YOUR method The name of the drug The average value of the intensity of pain in the knee joint when walking on a flat surface within the group before treatment, mm The average value of the intensity of pain in the knee joint when walking on a flat surface within the group after treatment (4 weeks after using the drug), mm Change in pain intensity after treatment, mm The drug "Pharmaskin THC" in the form of a cream 62 38 24 Example 1 52 28 28 Example 2 56 26 thirty Example 3 51 eighteen 33 Example 4 59 32 27

From table 1 it follows that among the five treatment options presented, the smallest value of the change in pain intensity is observed when using the drug Pharmaskin THC with one active substance - glucocosamine potassium sulfate chloride (24 mm).

Therefore, the developed pharmaceutical compositions containing glucosamine salt and methyl salicylate as active substances (in examples 3 and 4 also additionally contain lidocaine salt), have stronger analgesic properties.

The increase in the analgesic properties of the pharmaceutical composition is explained by the presence of methylsalicylate in the composition of NSAIDs (the pharmaceutical compositions of Examples 3-4 also contain a lidocaine salt).

When developing the pharmaceutical composition, there was concern that the use of methyl salicylate as an active substance would increase its toxicity, since methyl salicylate, being a derivative of salicylic acid, in its pure form is quite toxic.

From the report on preclinical toxicological studies (acute and subchronic toxicity, local irritating effect) of the drug “Glucosamine plus” (cream-gel), conducted in the State Scientific Center “GNTSLS”, Kharkiv, 08/05/2011, we can conclude that the toxicity developed a pharmaceutical composition containing glucosamine salt and methyl salicylate as active substances is within normal limits.

The achievement of the technical result of the invention in the form of increased analgesic properties does not occur to the detriment of the toxicity of the pharmaceutical composition.

List of references

1. Pokrovsky V.I. Small Medical Encyclopedia - Soviet Encyclopedia, 1996. - T.4. - 577 p.

2. ICD-10: International Statistical Classification of Diseases and Health Problems. In 3 volumes (in 4 books). - 10th ed. - Kazan: Medicine, 2003 .-- 2438 p.

3. Benevolenskaya L.I., Brzhezovsky M.M. Epidemiology of rheumatic diseases. - M .: Medicine, 1988 .-- 237 p.

4. Osteoarthrosis: modern principles of treatment [Electronic resource]. - V.V. Povoroznyuk, MD, professor, Institute of Gerontology, Academy of Medical Sciences of Ukraine, Kiev, 2003. - Access mode: http://health-ua.com/articles/469.html

5. Instructions for the use of the drug Pharmaskin THC.

6. A preclinical study of the chondroprotective properties of the drug “Glucosamine Plus” (cream gel), conducted at the National Pharmaceutical University of the Ministry of Health of Ukraine, Kharkov, 2011

7. Preclinical toxicological study (acute and subchronic toxicity, local irritating effect) of the drug “Glucosamine plus” (cream-gel), conducted in the State Enterprise “GNTsLS”, Kharkov, 05.08.2011.

8. A preclinical study of the specific pharmacological activity of the drug "Glucosamine Plus" (cream gel), conducted in the GP "GNTsLS" Kharkov, 08/05/2011

Claims (9)

1. A drug for the treatment of osteoarthritis, made in a soft dosage form containing glucosamine salt as an active substance, characterized in that it contains the following components:
- active substances:
glucosamine salt
methyl salicylate
- Excipients. 2. The drug according to claim 1, characterized in that it contains components in the following dosages, wt.%:
- active substances:
glucosamine salt - 0.5-10.0
methyl salicylate - 0.1-5.0
excipients - the rest is up to 100%. 3. The drug according to claim 1, characterized in that as the glucosamine salt mainly contains glucosamine hydrochloride in an amount of 5.00% wt. and contains methyl salicylate mainly in the amount of 2.50% wt. 4. The drug according to claim 1, characterized in that it contains components in the following dosages, wt.%:
- glucosamine hydrochloride - 0.5-10.0
- methyl salicylate - 0.1-5.0
- preservative (preservatives) - 0.0001-2.0
- antioxidant (antioxidants) - 0.05-2.0
non-aqueous solvent (s) - 5.0-60.0
- emulsifier (emulsifiers) - 0.5-15.0
- thickener - 0.1-7.0
- emollients - 3.0-80.0
- pH adjusting agent (s) - 0.1-2.0
- purified water - the rest is up to 100%. 5. The drug according to claim 1, characterized in that the active substance additionally contains lidocaine salt. 6. The drug according to claim 5, characterized in that it contains components in the following dosages, wt.%:
- active substances:
glucosamine salt - 0.5-10.0
methyl salicylate - 0.1-5.0
lidocaine salt - 0.1-5.0
- excipients - the rest is up to 100%. 7. The drug according to claim 5, characterized in that the glucosamine salt mainly contains glucosamine hydrochloride in an amount of 5.00% wt., As the lidocaine salt mainly contains lidocaine hydrochloride with a dosage of 1.00% wt. 8. The drug according to claim 5, characterized in that it contains components in the following dosages, wt.%:
- glucosamine hydrochloride - 0.5-10.0
- methyl salicylate - 0.1-5.0
- lidocaine hydrochloride - 0.1-5.0
- preservative (preservatives) - 0.0001-2.0
- antioxidant (antioxidants) - 0.05-2.0
- solvent (s) - 5.0-60.0
- emulsifier (emulsifiers) - 0.5-15.0
- thickener - 0.1-7.0
- emollients - 3.0-80.0
- pH adjusting agent (s) - 0.1-2.0
- purified water - the rest is up to 100%. 9. The drug according to any one of claims 1 to 8, characterized in that it can be made in the form of a cream-gel, cream, but is not limited to this.